A Randomized Trial Comparing Postoperative Adjuvant Chemotherapy with Cisplatin and 5-Fluorouracil Versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907)

Ando, Nobutoshi; Kato, Hoichi; Igaki, Hiroyasu; Sekiguchi, Masayuki; Ozawa, Soji; Shimizu, Hideaki; Nakamura, Tsutomu; Yabusaki, Hiroshi; Aoyama, Norio; Kurita, Akira; Ikeda, Kenichiro; Kanda, Tatsuo; Tsujinaka, Toshimasa; Nakamura, Kenichi; Fukuda, Haruhiko

doi:10.1245/s10434-011-2049-9

Cited by 1,139 publications

(855 citation statements)

References 17 publications

Supporting

Mentioning

833

Contrasting

Unclassified

Order By: Relevance

“…However, this method is only used for lower thoracic esophageal cancer. In Japan, a transthoracic esophagectomy with thorough lymph node dissection after neoadjuvant chemotherapy is a standard treatment method for localized esophageal cancer (Ando et al 2012). Our results may support this surgical strategy, since no differences in RLNP were observed according to tumor location and lymph node metastases along the RLN.…”

Section: Discussionsupporting

confidence: 65%

Recurrent Laryngeal Nerve Paralysis after Esophagectomy: Respiratory Complications and Role of Nerve Reconstruction

Koyanagi

Igaki

Iwabu

et al. 2015

Tohoku J. Exp. Med.

Self Cite

View full text Add to dashboard Cite

Recurrent laryngeal nerve paralysis (RLNP) after esophagectomy is a common complication and associated with aspiration pneumonia. In this study, we assessed the risk of RLNP and the usefulness of immediate reconstruction of recurrent laryngeal nerve (RLN) to prevent respiratory complications after esophagectomy. Seven hundred and eighty-two consecutive patients underwent an esophagectomy with three-field lymph node dissection, simultaneous gastric conduit reconstruction, and cervical anastomosis. Vocal cord function was observed using a flexible laryngoscope. Reconstruction between RLN and ipsilateral vagus nerve was performed during esophagectomy. RLNP was observed in 229 (29.3%) of the patients after esophagectomy: 198 unilateral and 31 bilateral cases. Of the 198 unilateral RLNP, vocal cord paralysis was observed predominantly on the left side (82.7%). RLNP was significantly associated with postoperative respiratory complications (P < 0.001) requiring a tracheotomy (P < 0.001) and mechanical ventilation (P < 0.001) and was also associated with esophagogastric anastomotic leakage (P = 0.015); consequently, the postoperative hospital stay was longer for patients with RLNP (P < 0.001). A longer operation time (P < 0.001) and advanced age (P = 0.038) were identified as significant independent predictors of RLNP. Resection of the RLN together with metastatic nodes was performed in 29 cases. The patients underwent RLN reconstruction (n = 11) had a significantly shorter postoperative hospital stay than those without RLN reconstruction (n = 18) (P = 0.019). In conclusion, RLNP was related to a poorer postoperative course among patients undergoing an esophagectomy. New surgical technologies are recommended for prevention of RLNP.

show abstract

Section: Discussionsupporting

confidence: 65%

Recurrent Laryngeal Nerve Paralysis after Esophagectomy: Respiratory Complications and Role of Nerve Reconstruction

Koyanagi

Igaki

Iwabu

et al. 2015

Tohoku J. Exp. Med.

Self Cite

View full text Add to dashboard Cite

show abstract

“…In patients with esophageal cancer, cisplatin (CDDP) is used as a neoadjuvant or as a post-operative adjuvant chemotherapy in combination with continuous infusion of 5-fluorouracil (5-FU) (4,5). When CDDP-based chemotherapy is administered, antiemetic drugs, such as dexamethasone (DEX), 5-HT 3 serotonin receptor antagonists or aprepitant are administered to prevent treatment-associated nausea and vomiting (6).…”

Section: Introductionmentioning

confidence: 99%

Effect of dexamethasone on extracellular secretion of cystatin C in cancer cell lines

et al. 2012

Self Cite

View full text Add to dashboard Cite

Abstract. The aim of the present study was to investigate dexamethasone (DEX)-induced secretion of cystatin C (Cys C) and the effect of cisplatin (CDDP) and 5-fluorouracil (5-FU) on Cys C secretion in human cancer cell lines. KYSE150, A549 and Caki-2 human cancer cell lines were cultured on plastic dishes and treated with DEX (100 nM) for 24, 48 and 72 h. KYSE150 cells were co-treated with DEX, CDDP (10 µM), and 5-FU (2 µM). The effects of DEX, CDDP and 5-FU on cell viability were evaluated. Results showed Cys C secretion levels in the culture medium of DEX-treated KYSE150 cells to be 1.8-to 2.3-fold higher compared to those in the culture medium of control cells. A similar tendency was observed in A549 cells at all the time points, whereas a significant increase in the Cys C secretion by Caki-2 cells was observed only 24 h after DEX treatment. Regarding KYSE150 cells, the secretion of Cys C was also enhanced by co-treatment of CDDP or 5-FU with DEX, although it was not affected by the co-administration of DEX and mifepristone, a glucocorticoid receptor antagonist. At concentrations that are typically used in esophageal cancer chemotherapy, CDDP and 5-FU demonstrated a moderate level of cytotoxicity in KYSE150 cells in contrast to DEX. These findings suggested that DEX has the potential to enhance the extracellular secretion of Cys C in esophageal cancer cells, possibly due to the transcriptional regulation mediated by glucocorticoid receptor activity. IntroductionCystatin C (Cys C) is a non-glycosylated cationic 13.3-kDa protein belonging to the cystatin superfamily of cysteine protease inhibitors (1-3). Cys C is produced by nucleated cells and is secreted into the blood at a constant rate (1-3). It is freely filtered through the glomerular membrane, completely re-absorbed and then catabolized in the proximal tubular cells (1-3). Thus, similarly to creatinine, the biological fate of Cys C is a good endogenous marker of the glomerular filtration rate (GFR).In patients with esophageal cancer, cisplatin (CDDP) is used as a neoadjuvant or as a post-operative adjuvant chemotherapy in combination with continuous infusion of 5-fluorouracil (5-FU) (4,5). When CDDP-based chemotherapy is administered, antiemetic drugs, such as dexamethasone (DEX), 5-HT 3 serotonin receptor antagonists or aprepitant are administered to prevent treatment-associated nausea and vomiting (6). A transient elevation was previously reported in serum Cys C concentration during the perioperative chemotherapy period in patients with esophageal cancer. We suggested that renal function estimates determined on the basis of serum Cys C levels during this treatment period might be misleading (7).To understand the effect of DEX and other drugs in detail, it is crucial to investigate the renal effects associated with serum Cys C concentration. The aim of this study was to investigate the ability of DEX to induce Cys C secretion in human cancer cell lines, as well as the effect of CDDP, 5-FU and mifepristone (RU-486) on Cys C secretion. Materials and metho...

show abstract

“…Olanzapine is classified as an atypical antipsychotic drug (27). Unlike typical antipsychotic drugs such as haloperidol and prochlorperazine, olanzapine has a weaker dopamine D 2 receptor blocking activity than typical antipsychotic drugs, although it acts on various receptors, including 5-HT 2A , 5-HT 2B , 5-HT 2C , 5-HT 3 , histamine H1, muscarinic m 1 , m 2 , m 3 , m 4 , and adrenergic α 1 receptors (28)(29)(30). Interestingly, increase in appetite or overeating is a well-known side-effect associated with olanzapine (31,32).…”

Section: Discussionmentioning

confidence: 99%

“…On the other hand, cisplatin with 5-FU regimen is recommended as neoadjuvant chemotherapy for stage II/III thoracic esophageal cancer and unresectable progressive recurrent esophageal cancer (4,5).…”

mentioning

confidence: 99%

Control of Nausea Based on Risk Analysis in Patients with Esophageal and Gastric Cancer Who Received Cisplatin-based Chemotherapy

Fujii

Iihara

Kajikawa

et al. 2017

View full text Add to dashboard Cite

Cisplatin is commonly used for esophageal and gastric cancer, however, the agent has high emetic risk, classified as highly emetic chemotherapy. Ohtsu et al. demonstrated in patients with advanced gastric cancer that 5-fluorouracil (5-FU) plus cisplatin led to a significantly higher tumor response rate and longer median progression-free survival but not overall survival as compared with 5-FU alone (1). Koizumi et al. also reported in phase 3 study comparing the effect of S-1 alone and its combination with cisplatin in patients with advanced gastric cancer that the combination was superior to S-1 alone in prolonging median progression-free survival (HR: 0.57; p<0.0001) as well as median overall survival (HR: 0.77; p=0.04) but led to more severe adverse drug reactions, including nausea and vomiting (2). Thus, oral fluoropyrimidine and cisplatin combination chemotherapy is currently used as the first-line treatment option for unresectable advanced gastric cancer. On the other hand, Bang et al. reported in patients with human epidermal growth factor receptor 2 (HER2)-positive gastric or gastro-oesophageal junction cancer that addition of trastuzumab (monoclonal antibody to HER2) to chemotherapy led to ignificantly longer median overall survival than chemotherapy alone (3). Thus, oral fluoropyrimidine, cisplatin and trastuzumab combination chemotherapy is currently regarded as the standard chemotherapy for HER2-positive gastric cancer.On the other hand, cisplatin with 5-FU regimen is recommended as neoadjuvant chemotherapy for stage II/III thoracic esophageal cancer and unresectable progressive recurrent esophageal cancer (4, 5).Cisplatin is classified as chemotherapy with high emetic risk (HEC) in several guidelines for prevention of chemotherapy-induced nausea and vomiting (CINV) (6-9). 6831

show abstract

A Randomized Trial Comparing Postoperative Adjuvant Chemotherapy with Cisplatin and 5-Fluorouracil Versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907)

Cited by 1,139 publications

References 17 publications

Recurrent Laryngeal Nerve Paralysis after Esophagectomy: Respiratory Complications and Role of Nerve Reconstruction

Recurrent Laryngeal Nerve Paralysis after Esophagectomy: Respiratory Complications and Role of Nerve Reconstruction

Effect of dexamethasone on extracellular secretion of cystatin C in cancer cell lines

Control of Nausea Based on Risk Analysis in Patients with Esophageal and Gastric Cancer Who Received Cisplatin-based Chemotherapy

Contact Info

Product

Resources

About